Serum Receptor Activator of Nuclear Factor-κ B Ligand, Osteoprotegrin, and Intact Parathyroid Hormone in Hemodialysis and Renal Transplant Patients

被引:6
|
作者
Rashtchizadeh, Nadereh [2 ]
Ghorbanihaghjo, Amir [1 ]
Argani, Hassan [2 ]
Meimand, Saeed Mahmoudi [2 ]
Safa, Javid [2 ]
Vatankhahan, Hamidreza [2 ]
Shahidi, Maryam [2 ]
机构
[1] Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz 51664, Iran
[2] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz 51664, Iran
关键词
Hemodialysis; Kidney transplanted patients; Osteoprotegrin; Serum receptor activator of nuclear factor-kappa B ligand; VASCULAR CALCIFICATION; BONE-RESORPTION; DISEASE; OSTEOCLASTOGENESIS; ATHEROSCLEROSIS; EXPRESSION; MARKERS; RATS; OPG;
D O I
10.1111/j.1744-9987.2012.01097.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Serum receptor activator of nuclear factor-? B ligand and osteoprotegrin are mediated to vascular calcification in the general population. Our knowledge is very sparse in hemodialysis and renal transplant patients. Receptor activator of nuclear factor-? B ligand, osteoprotegrin, intact parathyroid hormone, calcium, and phosphorus were measured in blood samples of 45 hemodialysis and 45 age-matched renal transplant patients. Osteoprotegrin (P = 0.001) and intact parathyroid hormone (P = 0.001) levels in the hemodialysis patients were higher than the renal transplant recipients. Osteoprotegrin had positive correlation with duration of dialysis and age in the hemodialysis (r = 0.88, P = 0.001 and r = 0.34, P = 0.02, respectively) and renal transplant patients (r = 0.92, P = 0.001 and r = 0.46, P = 0.001, respectively). Hemodialysis patients have higher osteoprotegrin levels than the renal transplant recipients. It may act as a protective factor for renal osteodystrophy or only as a secondary phenomenon of advanced renal failure.
引用
收藏
页码:600 / 604
页数:5
相关论文
共 50 条
  • [21] Relationship Between Serum Intact Parathyroid Hormone and Pruritus in Hemodialysis Patients
    Makhlough, Atieh
    Emadi, Naser
    Sedighi, Omid
    Khademloo, Mohamad
    Bicmohamadi, Amir Reza
    IRANIAN JOURNAL OF KIDNEY DISEASES, 2013, 7 (01) : 42 - 46
  • [22] Intact parathyroid hormone levels in renal transplant patients with normal transplant function
    Bleskestad, Inger H.
    Bergrem, Harald
    Leivestad, Torbjorn
    Goransson, Lasse G.
    CLINICAL TRANSPLANTATION, 2011, 25 (05) : E566 - E570
  • [23] Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
    Lorenz C. Hofbauer
    Armin E. Heufelder
    Journal of Molecular Medicine, 2001, 79 : 243 - 253
  • [24] Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
    Hofbauer, LC
    Heufelder, AE
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2001, 79 (5-6): : 243 - 253
  • [25] Multimerization of the receptor activator of nuclear factor-κB ligand (RANKL) isoforms and regulation of osteoclastogenesis
    Ikeda, T
    Kasai, M
    Suzuki, J
    Kuroyama, H
    Seki, S
    Utsuyama, M
    Hirokawa, K
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (47) : 47217 - 47222
  • [26] Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-κB ligand
    Yamamoto, Yohei
    Udagawa, Nobuyuki
    Matsuura, Sachiko
    Nakamichi, Yuko
    Horiuchi, Hiroshi
    Hosoya, Akihiro
    Nakamura, Midori
    Ozawa, Hidehiro
    Takaoka, Kunio
    Penninger, Josef M.
    Noguchi, Toshihide
    Takahashi, Naoyuki
    ENDOCRINOLOGY, 2006, 147 (07) : 3366 - 3374
  • [27] Expression of the receptor activator for nuclear factor-κB ligand and osteoprotegerin in chronic otitis media
    Kuczkowski, Jerzy
    Sakowicz-Burkiewicz, Monika
    Izycka-Swieszewska, Ewa
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2010, 31 (06) : 404 - 409
  • [28] Serum osteoprotegerin and receptor activator of nuclear factor-κB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?
    K. Kananen
    L. Volin
    K. Laitinen
    T. Ruutu
    M. J. Välimäki
    Osteoporosis International, 2006, 17 : 724 - 730
  • [29] Serum osteoprotegerin and receptor activator of nuclear factor-κB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients:: a role in bone loss?
    Kananen, K
    Volin, L
    Laitinen, K
    Ruutu, T
    Välimäki, M
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 (05) : 724 - 730
  • [30] Osteoprotegerin and receptor activator of nuclear factor-κB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls
    Vanderborght, A
    Linsen, L
    Thewissen, M
    Geusens, P
    Raus, J
    Stinissen, P
    JOURNAL OF RHEUMATOLOGY, 2004, 31 (08) : 1483 - 1490